September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
|Articles|November 9, 2021
Pharmacy Clinical Pearl of the Day: Alagille Syndrome
Author(s)Saro Arakelians, PharmD
Approximately 75% of people diagnosed with Alagille syndrome in childhood live to at least 20 years of age.
Advertisement
Clinical Pearl of the Day: Alagille Syndrome
Alagille syndrome is an inherited disorder that closely resembles other forms of liver disease seen in infants and young children.
Insight:
- Alagille syndrome causes liver damage. The liver produces bile to help remove waste from the body. It also helps digest fats and the fat-soluble vitamins A, D, E, and K. The body can use these vitamins only if they are combined with fat from the foods people eat. Bile ducts are the channels that move bile out of the liver.
- If a person does not have enough of these ducts, bile builds up in the liver, which damages liver tissues and ultimately can cause the liver to fail.
- Approximately 75% of people diagnosed with Alagille syndrome in childhood live to at least 20 years of age.
- Causes: Alagille syndrome is related to the JAG1 gene mutation.
- Symptoms include yellowish skin or eyes, itchy skin, delayed growth, hard skin bumps, heart murmur, and changes in the blood vessels.
- Treatment may include medications to increase bile flow (ursodeoxycholic acid), cholestyramine, rifampin, and naltrexone. Also, biliary diversion procedures that can help interrupt the normal bile circulation. Vitamin and special nutrition supplementation to support proper growth and development.
- Infants with Alagille syndrome are given a special formula that helps the small intestine absorb fats. The diet usually is high in calories, calcium, and with vitamins A, D, E, and K, and sometimes zinc.
- Liver transplantation, kidney surgery, and heart surgery may be other alternatives to correct any defects.
Sources:
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5